A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma [0.03%]
一项BLU-554（成纤维细胞生长因子受体4抑制剂）与CS1001（抗PD-L1）联合用于局部晚期或转移性肝细胞癌患者的Ib/II期研究
Mingzhen Zhou,Sihui Zhu,Chen Xu et al.
Mingzhen Zhou et al.
Objective: Targeted therapy combined with immunotherapy has become the main treatment option for hepatocellular carcinoma (HCC). This trial assessed the safety and efficacy of fibroblast growth factor receptor 4 inhibitor...
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides [0.03%]
超短单链聚脱氧核糖核苷酸的抗肿瘤活性
Alexander S Vedenkin,Sergey V Stovbun,Alexander A Bukhvostov et al.
Alexander S Vedenkin et al.
One of the features that differentiate cancer cells is their increased proliferation rate, which creates an opportunity for general anti-tumor therapy directed against the elevated activity of replicative apparatus in tumor cells. Besides D...
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells [0.03%]
孕激素系列的新五环衍生物和肉桂醛具有抗雌性和抗增殖作用，并在乳腺癌细胞中诱导凋亡
Alexander M Scherbakov,Svetlana K Vorontsova,Alvina I Khamidullina et al.
Alexander M Scherbakov et al.
The promising antitumor effects of progesterone derivatives have been identified in many studies. However, the specific mechanism of action of this class of compounds has not been fully described. Therefore, in this study, we investigated t...
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells [0.03%]
粘土乳酮B，一种天然的LSD1抑制剂，在体内外均可抑制前列腺癌细胞的增殖
Gaobo Yan,Hongyan Zhang,Yan Li et al.
Gaobo Yan et al.
Lysine-specific demethylase 1 (LSD1) has been a promising target to treat prostate cancer, and discovery of novel LSD1 inhibitors would have great clinical significance. In this work, viscosalactone B was first identified as a novel LSD1 in...
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study [0.03%]
奥希替尼及其两种活性代谢物AZ5104和AZ7550在日本晚期非小细胞肺癌患者中的群体药代动力学、药理基因组学和不良事件：前瞻性观察研究
Emi Ishikawa,Yuta Yokoyama,Haruna Chishima et al.
Emi Ishikawa et al.
Background: Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed to e...
Observational Study
Investigational new drugs. 2023 Feb;41(1):122-133. DOI:10.1007/s10637-023-01328-9 2023
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma [0.03%]
卡铂和紫杉醇联合用药作为纵隔癌一线治疗药物的研究
Hiroya Manaka,Satoshi Igawa,Michiko Yamamoto et al.
Hiroya Manaka et al.
Thymic carcinoma is a very rare neoplasm for which no optimal chemotherapeutic regimen has been established to date. Hence, we performed this study to investigate the efficacy and safety of carboplatin plus nanoparticle albumin-bound (nab)-...
Observational Study
Investigational new drugs. 2023 Feb;41(1):115-121. DOI:10.1007/s10637-023-01327-w 2023
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors [0.03%]
Mitazalimab（一种CD40激动型单克隆抗体）在晚期实体瘤患者中的I期静脉注射研究
Victor Moreno,Ruth Perets,Tamar Peretz-Yablonski et al.
Victor Moreno et al.
Mitazalimab is an agonistic human monoclonal antibody targeting CD40, a target for anti-tumor immunotherapy. This phase 1, dose-escalation study evaluated the safety, dose-limiting toxicities (DLTs), pharmacokinetic and pharmacodynamic prof...
Clinical Trial
Investigational new drugs. 2023 Feb;41(1):93-104. DOI:10.1007/s10637-022-01319-2 2023
DGG-300273, a novel WNT/β-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells [0.03%]
DGG-300273，一种新的WNT / β-连环蛋白抑制剂，可通过激活ROS-BIM信号在结肠癌细胞中以Wnt依赖性方式诱导凋亡细胞死亡
Do Yeon Kim,Yea Seong Ryu,Eun-Sil Lee et al.
Do Yeon Kim et al.
Dysregulated Wnt signaling is associated with malignant oncogenic transformation, especially in colon cancer. Recently, numerous drugs have been developed based on tumorigenesis biomarkers, thus having high potential as drug targets. Likewi...
Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma [0.03%]
勘误：TACE与乐伐替尼联合治疗作为最初不可切除的肝内胆管癌向手术转化的一种有前景的选择方案
Peng Yuan,Jinhua Song,Fei Wang et al.
Peng Yuan et al.
Published Erratum
Investigational new drugs. 2023 Feb;41(1):182. DOI:10.1007/s10637-022-01323-6 2023
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China [0.03%]
中国单中心、单臂一期研究中的II-III期非小细胞肺癌辅助特瑞帕利姆Ab联合铂类紫杉醇化疗方案
Helei Hou,Yongjie Wang,Dantong Sun et al.
Helei Hou et al.
Background: Neoadjuvant and adjuvant immune checkpoint inhibitor treatments for non-small cell lung cancer (NSCLC) patients with resectable disease have presented promising results. This is a phase I study to evaluate the...
Clinical Trial
Investigational new drugs. 2023 Feb;41(1):86-92. DOI:10.1007/s10637-022-01324-5 2023